Quoin Pharmaceuticals, Ltd. QNRX
We take great care to ensure that the data presented and summarized in this overview for Quoin Pharmaceuticals, Ltd. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in QNRX
Top Purchases
Top Sells
About QNRX
Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome. The company also offers three other pipeline products in development, which are also targeting rare skin diseases, including epidermolysis bullosa, Netherton Syndrome, and Scleroderma. Quoin Pharmaceuticals, Ltd. was incorporated in 2018 and is based in Ashburn, Virginia.
Insider Transactions at QNRX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 10
2024
|
Gordon Dunn Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
20,000
+30.2%
|
$0
$0.81 P/Share
|
|
Sep 09
2024
|
Gordon Dunn Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
8,856
+42.09%
|
$0
$0.79 P/Share
|
|
Sep 04
2024
|
Denise P. Carter Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
31,813
+29.8%
|
$0
$0.78 P/Share
|
|
Sep 04
2024
|
Michael Myers Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
37,094
+28.2%
|
$0
$0.74 P/Share
|
|
Sep 03
2024
|
Denise P. Carter Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
5,922
+17.59%
|
$0
$0.65 P/Share
|
|
Sep 03
2024
|
Michael Myers Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
800
+7.3%
|
$0
$0.62 P/Share
|
|
Jun 07
2024
|
Dennis Langer Director |
SELL
Open market or private sale
|
Direct |
297
-84.86%
|
$0
$0.73 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 104K shares |
|---|
| Open market or private sale | 297 shares |
|---|